Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

1 Receptor Agonist Product Portfolios and R&D Pipelines

 

4 ) Interferon

a) INTERFERON alpha

 

• Interferon alpha sales 2012 of branded products in regulated markets

• 1st generation Interferon alpha-2a in regulated markets

• 1st generation Interferon alpha-2a in non-regulated markets

• Next generation Interferon alpha-2a in regulated markets

• Next generation Interferon alpha-2a in non-regulated markets and biosimilars

• 1st generation Interferon alpha-2b in regulated markets

• 1st generation Interferon alpha-2b in non-regulated markets and biosimilars

• Next generation Interferon alpha-2b in regulated markets

• Next generation Interferon alpha-2b in non-regulated markets and biosimilars

• Other Interferon alpha sub-types

• Interferon alpha with not specified sub-type – 1/2

• Purified natural human interferon alpha

 

b) Consensus INTERFERONs

c) INTERFERON beta

 

• Interferon beta sales 2012 of branded products in regulated markets

• 1st generation Interferon beta-1a in regulated markets

• 1st generation Interferon beta-1a in non-regulated markets and biosimilars

• 1st generation Interferon beta-1b in regulated markets

• 1st generation Interferon beta-1b in non-regulated markets and biosimilars

• 1st generation Interferon beta with not disclosed sub-type

• Next generation Interferon beta in regulated markets

• Purified natural human interferon beta

 

d) INTERFERON gamma

e) Other INTERFERONs

5 ) Insulin

 

• 2012 Sales of branded recombinant human insulins in regulated markets

• 2012 Sales of branded short-acting recombinant human insulin analogs in regulate
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , November 21, 2014 , ... responsable comercial   Mariano Rodríguez es elegid ... KLOX está en marcha para comenzar de ... cura de heridas de reciente aprobación en Europa   , ... compañía") se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) and ... PCI, Inc., leading suppliers of ozone process technology ... to provide a new state-of-the-art ozone system for ... Wastewater Treatment. The new ozone disinfection system ... dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ozone ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... $1,036,024, or 89%, for the nine months ended September 30, ... ... 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai,Cactus Bio-tech Inc. (OTC Bulletin Board: CKGT), a ... filed its quarterly report on SEC Form 10QSB on November,19, 2007 and ...
... Dramatically Enhances the Way Ultrasound, Departments Work and Provides a ... ... Applications, CHICAGO, Nov. 26 At the 93rd Scientific ... from,Nov. 25 to 30 at McCormick Place (Booth 7713, Hall B), ...
... to Integrate with Multiple Disparate PACS and ... ... CHICAGO, Nov. 26 RSNA Booth #5924 -- ... and,interoperability between diagnostic acquisition devices, PACS, HIS, RIS,and related ...
Cached Biology Technology:China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 4Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 2Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 3Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 4Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 5Siemens' New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow 6E-Rad Solutions Selects Compressus' Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market 2E-Rad Solutions Selects Compressus' Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market 3
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... Federation of American Societies for Experimental Biology (FASEB) announces ... (SRC): Mobile DNA in Mammalian Genomes. Mobile elements ... the structure and altering functions within mammalian genomes, and ... explore the explosion of data from high throughput sources, ...
... This release is available in French . ... on the brain,s ability to be plastic that is to ... study from the Montreal Neurological Institute The Neuro, McGill University, ... nervous system known as netrin, plays a key role in regulating ...
... defines and names groups of organisms is a ... methods used during the beginnings of the discipline in ... information to delineate new species, the study of the ... of taxonomists. These studies often require first-hand examination of ...
Cached Biology News:Finding the way to memory 2Finding the way to memory 3Biodiversity exploration in the 3-D era 2
Similar to proteasome (prosome, macropain) 26S subunit, ATPase, 1 Antigen: Recombinant Protein...
RABBIT ANTI AMPHOTERIN...
See product name for description....
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
Biology Products: